Rationality evaluation of human albumin in the treatment of liver cirrhosis based on weighted TOPSIS method

LIU Lu; ZHENG Danwei; XU Lejia

doi:10.6039/j.issn.1001-0408.2022.23.19

您当前的位置：

首页 >

文章列表页 >

Rationality evaluation of human albumin in the treatment of liver cirrhosis based on weighted TOPSIS method

更新时间：2023-02-22

- Rationality evaluation of human albumin in the treatment of liver cirrhosis based on weighted TOPSIS method
- ZHONGGUO YAOFANG Vol. 33, Issue 23, Pages: 2917-2920(2022)
- 作者机构：
  
  中山大学附属第三医院药剂科，广州　510630
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2022.23.19
  CLC： R969.3;R575.2;R973⁺.5
- Published：15 December 2022，
  
  Received：15 May 2022，
  
  Revised：08 October 2022，
扫描看全文
刘露,郑丹微,徐乐加.加权TOPSIS法评价人血白蛋白治疗肝硬化的合理性 ^Δ[J].中国药房,2022,33(23):2917-2920.

LIU Lu,ZHENG Danwei,XU Lejia.Rationality evaluation of human albumin in the treatment of liver cirrhosis based on weighted TOPSIS method[J].ZHONGGUO YAOFANG,2022,33(23):2917-2920.
刘露,郑丹微,徐乐加.加权TOPSIS法评价人血白蛋白治疗肝硬化的合理性 ^Δ[J].中国药房,2022,33(23):2917-2920. DOI： 10.6039/j.issn.1001-0408.2022.23.19.

LIU Lu,ZHENG Danwei,XU Lejia.Rationality evaluation of human albumin in the treatment of liver cirrhosis based on weighted TOPSIS method[J].ZHONGGUO YAOFANG,2022,33(23):2917-2920. DOI： 10.6039/j.issn.1001-0408.2022.23.19.

摘要

目的

基于加权逼近理想排序法（TOPSIS）建立人血白蛋白（HA）用于肝硬化治疗的药物利用评价标准，并对HA药物利用情况进行综合评价。

方法

以HA的说明书为基础，参照国内外相关肝硬化治疗指南和HA处方点评办法制定HA药物利用评价标准，利用加权TOPSIS法对2020年我院感染科诊断为肝硬化的住院患者使用HA的情况进行合理性评价。

结果

制定的HA药物利用评价标准包括基线检查、适应证、禁忌证、联合用药、用法用量等8个评价指标，并通过咨询专家设定了评分权重。评价我院1 068份病历使用HA情况与最优方案和最劣方案的接近程度值（

），结果显示评价为合理病历（

≥0.8）有133份（12.45%），基本合理病历（0.6≤

＜0.8）有576份（53.93%），不合理病历（

＜0.6）有359份（33.61%）。主要的不合理问题为未进行基线检查、非适应证用药、禁忌证用药等。

结论

基于加权TOPSIS法制定的HA药物利用评价标准可以用于该药的合理使用评价。我院HA在肝硬化患者中的使用较合理，应继续加强管理，以减少或避免不合理用药情况。

Abstract

OBJECTIVE

To establish the drug use evaluation criteria of human albumin （HA） in the treatment of liver cirrhosis based on weighted technique for order preference by similarity to ideal solution （TOPSIS） method， and to comprehensively evaluate the utilization of HA.

METHODS

The drug use evaluation criteria of HA was established with reference to guidelines of liver cirrhosis treatment at home and abroad and HA prescription evaluation method， based on the HA instructions. The weighted TOPSIS method was used to evaluate the rationality of HA drug use in inpatients with liver cirrhosis diagnosed by the infection department of our hospital in 2020.

RESULTS

The established drug use evaluation criteria for HA included 8 evaluation indicators， i.e. baseline examination， indication， contraindication， combined use of drugs， usage and dosage， and so on； the scoring weight was set by consulting experts. According to the evaluation of the closeness degree （

） between the HA drug use of 1 068 medical records and the optimal plan and the worst plan in our hospital， the result showed that 133 （12.45%） were evaluated as reasonable medical records （

≥0.8）， 576 （53.93%） as basically reasonable medical records （0.6≤

＜0.8）， and 359 （33.61%） as unreasonable medical records （

＜0.6）. The main unreasonable problems were the absence of baseline examination， non-indication medication， medication for contraindication， etc.

CONCLUSIONS

The drug use evaluation criteria of HA based on the weighted TOPSIS method can be used to evaluate the rational use of the drug. The drug use of HA in patients with liver cirrhosis in our hospital is reasonable， and we should continue to strengthen the management to reduce or avoid unreasonable drug use.

关键词

人血白蛋白肝硬化加权逼近理想排序法合理用药

Keywords

liver cirrhosisweighted TOPSIS methodrational drug use

references

国家卫生健康委员会.北京市医疗机构处方专项点评指南：试行[EB/OL].（2012-12-28）.[2022-03-04].http：//www.nhc.gov.cn/yzygj/s3590/201212/93a34b9643bc47c5acf138228c69a60e.shtmlhttp://www.nhc.gov.cn/yzygj/s3590/201212/93a34b9643bc47c5acf138228c69a60e.shtml.

徐小元，丁惠国，李文刚，等.肝硬化诊治指南[J].临床肝胆病杂志，2019，35（11）：2408-2425.

徐小元，丁惠国，李文刚，等.肝硬化腹水及相关并发症的诊疗指南[J].实用肝脏病杂志，2018，21（1）：21-31.

鲁松，杨萍，杨黎，等.人血白蛋白注射液的药品评价研究进展[J].中国药物警戒，2022，19（2）：228-232.

袁浩宇，林勇，胡明，等.药物利用评价标准建立的方法探讨及实践[J].中国药房，2010，21（22）：2101-2104.

程乾生.属性层次模型AHM：一种新的无结构决策方法[J].北京大学学报（自然科学版），1998，34（1）：10-14.

刘继斌，曲成毅，王瑞花.基于属性AHM的Topsis综合评价及其应用[J].现代预防医学，2006，33（10）：1862-1863.

邢蓉，宋佳伟，许健，等.头孢哌酮舒巴坦基于加权TOPSIS法的药物利用评价[J].中国医院药学杂志，2014，34（15）：1273-1278.

李慧博，门鹏，王宇，等.《人血白蛋白用于肝硬化治疗的快速建议指南》解读[J].临床药物治疗杂志，2018，16（12）：10-16.

CARACENI P，ANGELI P，PRATI D，et al. AISF-SIMTI position paper：the appropriate use of albumin in patients with liver cirrhosis[J]. Trasfusione Del Sangue，2016，14（1）：8-22.

CARACENI P，ANGELI P，PRATI D，et al. AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis：a 2020 update[J]. Trasfusione Del Sangue，2021，19（1）：9-13.

European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol，2018，69（2）：406-460.

YOSHIJI H，NAGOSHI S，AKAHANE T，et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020[J]. J Gastroenterol，2021，56（7）：593-619.

AITHAL G P，PALANIYAPPAN N，CHINA L，et al. Guidelines on the management of ascites in cirrhosis[J]. Gut，2021，70（1）：9-29.

曾晶，徐萍，王清，等. 8 760例住院患者人血白蛋白临床使用分析与评价[J].中国药房，2017，28（8）：1027-1030.

张婷，吴慧，卞海林，等.我院人血白蛋白临床合理使用评价标准的建立与应用[J].中国药房，2016，27（20）：2752-2755.

吴柳婷，白敦耀，黄艳芳，等.应用属性层次分析法加权TOPSIS法评价我院头孢西丁用药合理性[J].中国药房，2017，28（20）：2759-2763.

张红，宋佳伟，陈雷，等.加权TOPSIS法对围手术期抑酸药预防应激性溃疡的合理性评价[J].药物流行病学杂志，2021，30（4）：271-275.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application and evaluation of management mode for the use of antimicrobial drugs in county-level medical communities led by anti-infective clinical pharmacists

Expert consensus on comprehensive clinical evaluation of antidepressant drugs

Effect of posaconazole combined with proton pump inhibitors on blood concentrations and invasive fungal infection in patients with malignant hematological disorders

Clinical comprehensive evaluation of Chinese patent medicine for the treatment of chronic hepatitis B

Comparison of two analysis methods of opioid consumption sum in medical institutions

Related Author

DENG Xiaoqin

ZHAO Chi

LI Zhaohong

YAN Hongyan

SHEN Dongfang

TAN Helang

JIANG Mingzhong

DENG Nanjun

Related Institution

Dept. of Pharmacy， Zhongxian People’s Hospital of Chongqing， Chongqing Zhongxian

Psychic Health Research Institute， the Second Xiangya Hospital of Central South University

Shanghai Mental Health Center Affiliated to Shanghai Jiao Tong University School of Medicine/National Center for Mental Disorder

Peking University Sixth Hospital/National Clinical Research Center for Psychiatric and Mental Disorders

Dept. of Hematology， the First Hosptial of Hebei Medical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰